Dr. Frasier earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug-discovery research in Parkinson's and Alzheimer's disease.
Currently Mark is Senior Vice President, Research Programs, at the Michael J. Fox Foundation. Mark co-manages a team of research professionals who stay closely linked to the Parkinson’s research community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson’s disease. Mark regularly meets with academic and industry researchers around the world to identify promising proposals to support, providing troubleshooting and ongoing management of projects as they go forward. He also supports the Foundation’s priority interest in developing biomarkers for Parkinson’s disease that will accelerate clinical trials of new drugs.
Mark has been an invited speaker at global neuroscience and biomarker conferences and has published numerous articles in the area of Parkinson’s disease biomarkers, drug development, and data sharing. He sits on several advisory boards including the Alzheimer’s Disease Neuroimaging (ADNI) and Parkinson’s Progression Marker Initiative (PPMI) Steering Committees.
Creating a Coordinated Path Forward: Biomarkers in Drug Discovery and Clinical Practice
11:20 AM - 12:10 PM